Financial Performance - The total revenue for the year ended December 31, 2025, was RMB 131,509,000, with a gross profit of RMB 117,057,000[4]. - The company reported a pre-tax loss of RMB 341,363,000 for 2025, compared to a loss of RMB 174,690,000 in 2024[4]. - The company incurred a net loss of RMB 341.4 million for the year 2025, compared to a net loss of RMB 174.7 million in 2024, reflecting ongoing investment in growth[67][68]. - Other income decreased by RMB 6.4 million from RMB 20.1 million in 2024 to RMB 13.7 million in 2025, primarily due to reduced investment income from structured deposits and the absence of asset disposal gains[28]. - The group reported a pre-tax loss of RMB 341,363,000 for 2025, compared to a loss of RMB 174,690,000 in 2024[86]. - The company reported a basic loss per share of RMB 0.787 for 2025, compared to RMB 0.416 for 2024, reflecting an increase in losses of 88.9%[90]. Research and Development - Research and development expenses increased significantly to RMB 205,779,000 from RMB 102,511,000 in the previous year, indicating a focus on innovation[4]. - The company has established an AI drug discovery platform to enhance its capabilities in developing innovative therapies for metabolic diseases[6]. - The group continues to prioritize early pipeline assets in metabolic diseases, focusing on T1D, MASH, AD, T2D, and obesity, with several candidates in preparation for IND submission by 2026[17]. - R&D expenses increased significantly from RMB 102.5 million in 2024 to RMB 205.8 million in 2025, a rise of RMB 103.3 million, mainly due to increased costs for raw materials and clinical trials[30]. - The company is exploring new applications for Isupatide α, including veterinary uses for diabetes and obesity, with clinical trial applications submitted in early 2026[6]. Product Development and Commercialization - The core product, Isupatide α, was approved for treating T2D in China and was commercialized in February 2025, with inclusion in the National Medical Insurance Drug List effective January 1, 2026[5][8]. - The company is expanding its distribution network and strategic partnerships to enhance the commercialization of Isupatide α, anticipating continued progress in 2026[9]. - The group is advancing the development of Icosapent Ethyl α for adolescent weight management, addressing a growing clinical need in a new indication area[14]. - The group plans to advance the commercialization of its product in Hong Kong in 2026, including pricing and market strategy evaluations[52]. - The group aims to initiate pre-commercialization preparations for weight management indications following the announcement of Phase III data[53]. Financial Position - The net asset value increased to RMB 1,053,397,000 in 2025 from RMB 796,471,000 in 2024, reflecting a strong financial position[4]. - Total current assets increased to RMB 1.48 billion in 2025, up from RMB 839.2 million in 2024, indicating improved liquidity[69]. - The company's total equity rose to RMB 1.05 billion in 2025, compared to RMB 796.5 million in 2024, reflecting a stronger financial position[70]. - Current assets increased from RMB 701.0 million as of December 31, 2024, to RMB 974.4 million as of December 31, 2025, mainly due to proceeds from a global offering[39]. - The debt-to-asset ratio rose from approximately 15% on December 31, 2024, to about 33% on December 31, 2025[40]. Expenses and Costs - The cost of sales recorded was RMB 14.5 million, attributed to the accounting policy that recognizes pre-commercialization manufacturing costs as R&D expenses[25]. - Administrative expenses decreased from RMB 84.5 million in 2024 to RMB 77.4 million in 2025, a reduction of RMB 7.1 million, primarily due to lower employee benefits costs[34]. - Sales and distribution expenses surged from RMB 2.4 million in 2024 to RMB 176.6 million in 2025, driven by increased marketing and promotional activities[36]. - Other expenses rose from RMB 4.5 million in 2024 to RMB 10.6 million in 2025, mainly due to foreign exchange losses and donations[37]. - Financial costs increased from RMB 0.9 million in 2024 to RMB 1.7 million in 2025, attributed to higher interest on bank loans[38]. Strategic Initiatives - The company has utilized RMB 39.3 million of the net proceeds from its IPO, which totaled RMB 645.2 million, primarily for clinical trials and commercialization efforts[63][64]. - The company plans to allocate 55.4% of the IPO proceeds (RMB 357.4 million) towards further clinical trials for its obesity treatment, expected to continue into 2026 and 2027[64]. - The group is exploring next-generation long-acting formulations of Icosapent Ethyl α based on a proprietary injectable hydrogel delivery platform, targeting administration intervals of three to six months[20]. - The group plans to register its product in selected overseas markets, including Southeast Asia and Latin America, and seeks strategic partnerships for commercialization[56]. - The company is actively monitoring regulatory changes from the National Medical Products Administration[102]. Governance and Compliance - The group has adopted high standards of corporate governance to protect shareholder interests and enhance corporate value[58]. - The audit committee has reviewed the financial statements and confirmed compliance with relevant accounting standards and regulations[60]. - The board of directors includes a diverse group of executives and independent directors, enhancing governance[104]. - The company is committed to adhering to the listing rules set by the Hong Kong Stock Exchange[101].

廣州銀諾醫藥集團股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）董 事（「董事」）會（「董事會」）謹此宣佈，施雪玲女士（「施女士」）已辭任(i)本公司 聯席公司秘書（「聯席公司秘書」）、(ii)本公司法律程序文件代理人（根據香港法 例第622章公司條例第16部在香港代本公司接收法律程序文件和根據香港聯合交 易所有限公司（「聯交所」）證券上市規則（「上市規則」）第19A.13(2)條在香港代本 公司接收法律程序文件或通知之法律程序文件代理人（統稱「法律程序文件代理 人」）），以及(iii)擔任根據上市規則第3.05條的本公司授權代表（「授權代表」），基 於個人職業發展原因，自2026年3月23日起生效。 施女士已確認，彼與董事會並無意見分歧，亦無與其辭任有關的事宜需提請聯交 所或本公司股東（「股東」）垂注。董事會亦不知悉任何其他有關其辭任而須提請股 東及聯交所垂注的其他事宜。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou I ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 本年度虧損增加主要由於(i)研發開支增加約人民幣103.3百萬元，主要由於與依蘇 帕格魯肽α的生命週期管理及臨床開發相關的原材料、臨床前研究、臨床試驗及 工藝優化開銷的增加，包括中國用於治療肥胖及超重的IIb/III期臨床試驗及澳大 利亞的II期臨床研究；及(ii)銷售及分銷開支增加約人民幣174.3百萬元，主要歸因 於依蘇帕格魯肽α商業化上市後營銷及推廣開支增加，以及為支持市場開發擴充 銷售隊伍導致僱員福利開支增加。 本公告所載資料基於董事會於審閱本集團本年度的未經審核綜合管理賬目及董事 會現時可得的資料後進行的初步評估。該等資料未經本公司外聘核數師審核或審 閱，亦未經董事會審核委員會審閱，並可能會作出調整。本集團本年度實際業績 可能與本公告內所載數據有所差異。敬請本公司股東及潛在投資者參考將於2026 年 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2591） 內幕消息 擬實施H股全流通計劃 本公告乃廣州銀諾醫藥集團股份有限公司（「本公司」）根據香港聯合交易所有限公 司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章證 券及期貨條例第XIVA部之內幕消息條文刊發。 茲提述(i)中國證券監督管理委員會（「中國證監會」）於2019年11月14日頒佈、並 於2023年8月10日進一步修正的《H股公司境內未上市股份申請「全流通」業務指 引》（「《指引》」）；及(ii)中國證監會於2023年2月17日頒佈的《境內企業境外發行證 券和上市管理試行辦法》。 根據《指引》，本公司董事（「董事」）會（「董事會」）欣然公告，於2026年3月17日， 本公 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 （股份代號：2591） 董事會會議通告 廣州銀諾醫藥集團股份有限公司（「本公司」）之董事（「董事」）會（「董事會」）謹此 宣佈，董事會會議將於2026年3月23日（星期一）舉行，藉以（其中包括）考慮及批 准本公司及其附屬公司截至2025年12月31日止年度之全年業績及其刊發。 承董事會命 廣州銀諾醫藥集團股份有限公司 董事長 WANG QINGHUA博士 中華人民共和國，上海，2026年3月10日 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） 於本公告日期，董事會包括執行董事WANG QINGHUA博士、姜帆女士、徐文潔 女士及黃冰先生；非執行董事HO KYUNG SHIK先生及衡磊先生；及獨立非執行 董事陶武平先生、宋瑞霖博士及陳向榮先生。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州銀諾醫藥集團股份有限公司（於中華人民共和國成立的股份有限公司） 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02591 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 420,285,370 | RMB | 1 | RMB | | 420,285,370 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 2. 股份分類 | ...

Group 1 - Tencent Holdings (00700) had a net inflow of 4.316 billion, representing a 22.17% increase in net inflow ratio [2][3] - Alibaba-W (09988) experienced a net inflow of 1.658 billion, with a net inflow ratio of 13.70% [2][3] - Pop Mart (09992) saw a net inflow of 588 million, with a net inflow ratio of 17.52% [2][3] Group 2 - Kangfang Biotech (09926) faced a net outflow of -285 million, with a net outflow ratio of -33.89% [2][3] - Yingfu Fund (02800) had a net outflow of -248 million, with a net outflow ratio of -1.88% [2][3] - Yum China (09987) recorded a net outflow of -213 million, with a net outflow ratio of -30.90% [2][3] Group 3 - Huaxia Hang Seng Technology (03088) led in net inflow ratio at 89.30% with a net inflow of 54.532 million [2][3] - Southern East Selection (03441) followed with a net inflow ratio of 68.86% and a net inflow of 14.5209 million [2][3] - China Foods (00506) had a net inflow ratio of 59.26% with a net inflow of 4.9995 million [2][3] Group 4 - Jinyuan International (02232) had the highest net outflow ratio at -50.27% with a net outflow of -40.079 million [3] - iFlytek Medical Technology (02506) recorded a net outflow ratio of -49.63% with a net outflow of -15.2262 million [3] - Sinopec Crown (00934) had a net outflow ratio of -45.08% with a net outflow of -5.1472 million [3]

Group 1 - The core announcement is that Jin Jin has resigned as co-secretary of the company for personal development reasons, effective February 6, 2026 [1] - Yang Dongyan has been appointed as the new co-secretary of the company, also effective February 6, 2026 [1]

Group 1 - The company announced that Ms. Jin Jin has resigned as co-secretary for personal development reasons, effective from February 6, 2026 [1] - Ms. Yang Dongyan has been appointed as co-secretary, effective from February 6, 2026, and will work alongside the current co-secretary, Ms. Shi Xueling [1]

Group 1 - The company announced the resignation of Ms. Jin Jin as co-secretary due to personal development reasons, effective from February 6, 2026 [1] - Ms. Yang Dongyan has been appointed as co-secretary, effective from February 6, 2026, and will work alongside the current co-secretary, Ms. Shi Xueling [1]